From: rpautrey2 on 15 Oct 2009 16:56
(Aribert Deckers' Says, "No need to study and no time. I am an
On Oct 15, 2:30 pm, Happy Oyster <happy.oys...(a)ariplex.com> wrote:
> On Thu, 15 Oct 2009 07:17:53 -0500, "t" <tool...(a)gmail.com> wrote:
> > Worth posting again.
> Deadly Disease Eliminated in Children under Five Years of Age in Uganda
> Deadly Disease Eliminated in Children under Five Years of Age in Uganda
> Nearly 100 Percent Drop in Hib Meningitis as a Result of Widespread Vaccination
> GENEVA, SWITZERLAND, 10 March 2008 - Hib meningitis has been virtually
> eliminated in young children in Uganda just five years after the country
> introduced Haemophilus influenzae type b (Hib) vaccine nationwide, according to
> an independent study.
> Haemophilus influenzae type b is a leading cause of pneumonia and meningitis, an
> inflammation of the lining covering the brain and spinal cord. Each year, Hib
> kills approximately 400,000 children under five years of age, most of them in
> the developing world. It is also responsible for approximately three million
> cases of serious illnesses resulting in long-term consequences such as deafness,
> paralysis, mental retardation and learning disabilities. The positive results
> are outlined in a study to be published in the April issue of The Bulletin of
> the World Health Organization, an independent peer-reviewed international public
> health journal. Advanced publication of the study can be found athttp://www.who.int/bulletin/publish_ahead_of_print/en/index.html
> Upon monitoring occurrence of bacterial meningitis due to Hib between 2001 to
> 2006, the study’s authors saw marked decline in the disease resulting from
> implementation of a new vaccination program. Where monitored, the incidence rate
> dropped by 85 percent within four years of vaccine introduction and fell to zero
> in the fifth year. The authors estimate that Hib vaccine in the Ugandan
> immunisation programme now prevents almost 30,000 cases of severe Hib disease
> and 5,000 child deaths (under five years) annually, equivalent to the successful
> control of measles in the country.
> Funding for Hib vaccine is a major part of the GAVI Alliance's (formerly known
> as the Global Alliance for Vaccines and Immunisation) programme support to
> Uganda. With GAVI support, Uganda was able to introduce 16.5 million doses of
> Hib vaccines nationwide from 2002 to 2006. The government chose to use what is
> known as a pentavalent vaccine - a 5 in 1 injection that includes vaccines for
> Hib as well as diphtheria, pertussis, tetanus, and hepatitis B.
> "GAVI welcomes these extremely positive results" said Dr Julian Lob-Levyt,
> Executive Secretary of the GAVI Alliance. "Thanks to the collaborative efforts
> of the Ugandan Ministry of Health, the WHO, UNICEF and other partners, we can
> applaud a true success in controlling this deadly disease that has too often
> claimed so many lives."
> Uganda was one of the first GAVI-eligible countries to adopt Hib vaccine,
> preceding what is now a global trend. According to a recent report released by
> WHO, the Centers for Disease Control and Prevention and the Hib Initiative,
> between 2004 and 2007 the proportion of the 72 poorest countries eligible for
> GAVI support using or approved to use Hib vaccine increased from 18 percent to
> 65 percent. In November, the GAVI board approved additional funding for Hib
> vaccine, bringing the total number of countries with approved proposals to 44.
> "This is excellent news for the future generations of Ugandanchildren. Uganda
> has been afrontrunner in the Africa region in adopting this life-saving vaccine.
> The leadership of early introducers such as Uganda, Kenyaand The Gambia
> hasstronglyinfluencedthe decisions of many other countries in the region to
> adoptHib vaccine. Today, 83% of the GAVI-eligible countries in Africa have now
> included or will soon include Hib vaccine in their national immunization
> programmes” says Rana Hajjeh, Director of the Hib Initiative.
> "We are proud of the results of this study. It's encouraging to know that these
> kinds of interventions in Uganda and elsewhere are making a significant
> contribution towards achieving the Millennium Development Goal of reducing
> mortality in children less than 5 years of age," says Dr Sam Zaramba, Director
> General of Uganda Ministry of Health "And GAVI's support was catalytic in
> allowing us to tackle this disease quickly and efficiently."
> The Government of Uganda recently committed national resources to procure Hib
> vaccine for its infant immunisation programme, in line with the GAVI
> co-financing policy.
> "The introduction of Hib vaccine has now completely changed the epidemiology of
> bacterial meningitis in Uganda, with elimination of meningitis due to Hib as a
> public health problem" says Dr Kekitiinwa - Pediatrician at Mulago Hospital,in
> Kampala Uganda, co-author of the study. "High quality surveillance has allowed
> us to understand and monitor those trends to ensure the quality of the
> immunisation programme, improve collaboration between clinicians and
> laboratories and inform on drug susceptibility for the common organisms."
> Although Hib vaccines for infants were first licensed in 1991 and have since
> been widely adopted in industrialised countries, they have not been used
> extensively in the developing world due to multiple barriers such as limited Hib
> disease awareness, uncertainty about the burden of disease and concerns about
> the financial and logistical implications of vaccine introduction. It took
> almost 15 years for the Hib vaccine to be introduced in developing countries
> after it was first licensed.
> There are efforts underway to bridge this gap by reducing the number of years
> developing countries have to wait to benefit from new vaccines. In 2007, a pilot
> Advance Market Commitment (AMC) was announced, aiming at accelerating the
> introduction of new vaccines in poor countries.
> The Uganda results follow similar results found in Bangladesh, Kenya, Chile, the
> Gambia, the United Kingdom, and United States. These studies have all concluded
> that Hib vaccine cuts the incidence of disease by 88% or more within 3 to 5
> In July 2007, a study from Bangladesh showed that routine immunisation of
> infants with a Hib conjugate vaccine prevented over one third of
> life-threatening pneumonia cases and approximately 90% of Hib meningitis cases.
> A Kenyan study in 2006 showed that the Hib vaccine cut the incidence of disease
> by 88% within 3 years. The authors say that vaccinating against the bacterium
> Haemophilus influenzae type b prevented approximately 3,370 Kenyan children from
> being hospitalised in 2005.
> The authors say that prior studies have shown that for every child with Hib
> meningitis in developing countries, there may be 5 to 10 others with Hib-related
> pneumonia, which is also preventable by vaccination. To achieve results more
> quickly, the WHO position paper on Hib vaccine recommends that children at
> highest risk, those under 2 years of age, be offered immunization at the time of
> vaccine introduction.
> The GAVI Alliance
> The GAVI Alliance is a public-private partnership of major stakeholders in
> vaccines and immunisation. It includes developing country and donor governments,
> the World Health Organization, UNICEF, the World Bank, the vaccine industry in
> both industrialised and developing countries, research and technical agencies,
> NGOs, the Bill & Melinda Gates Foundation and other private philanthropists. WHO
> projections show that GAVI support has prevented more than 2.9 million future
> deaths by the end of 2007.
> GAVI's efforts are critical to achieving the Millennium Development Goal on
> child health, which calls for reducing childhood mortality by two thirds by
> 2015. Of the 10 million children who die before reaching their fifth birthday
> every year, 2.5 million die from diseases that could be prevented with currently
> available or new vaccines.
> For more information, please visit:http://www.gavialliance.org
> The Hib Initiative
> In December 2005, the GAVI Alliance launched a $37 million program called the
> Hib Initiative, which unites infectious disease experts from Johns Hopkins
> Bloomberg School of Public Health, the London School of Hygiene and Tropical
> Medicine, the U.S. Centers for Disease Control and Prevention (CDC), and WHO to
> advance evidence-informed decision-making regarding the use of Hib vaccine in
> the developing world. An estimated 3 million cases of Hib disease occur each
> year in children under the age of 5 years, resulting in approximately 400,000
> deaths. For
> more information, please visit:http://www.hibaction.org
> For more information, please contact:
> GAVI Alliance:
> Jeffrey Rowland, (Geneva)
> +41 22 909 7165 office
> + 41 79 240 45 59 mobile
> jrowland [bat] gavialliance.org
> Carol Vieira (New York)
> +1 (401) 714-0821 office
> +1 (571) 723.2432 mobile
> CVieira [bat] burnesscommunications.com
> Photo requests:
> Sandra Scolari
> +41 22 909 6528 office
> sscolari [bat] gavialliance.org
> Michel Aublanc (Paris)
> +33 6 08 71 97 95 mobile
> michel.aublanc [bat] wanadoo.fr
> Cathy Bartley (London)
> +44 208 694 9138 office
> +44 795 856 1671 mobile
> cathy.bartley [bat] bartley-robbs.co.uk
> Claudio Tanca(Rome)
> +39 06 697 6661 office
> +39 347 530 9256 mobile
> ctanca [bat] apcoworldwide.com
> Download athttp://www.gavialliance.org/media_centre/videos/broadcast/index.php
> Hib Initiative:
> Lois Privor-Dumm
> +1 410 502 4292 office
> +1 484 354 8054 mobile
> lprivord [bat] jhsph.edu
> Vaccination saves lives!
> Schwerer Pfusch Arzneimittelprüfung